Ark Biopharmaceutical Announces NMPA Acceptance and Priority Review of New Drug Application for Ziresovir for Treatment of RSV Infection
December 08, 2022 20:00 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical), a biopharma company dedicated to the discovery and development of drugs for...
Statement on the Pediatric Surge From Federally Funded Pediatric Groups
November 09, 2022 09:00 ET
|
Pediatric Pandemic Network
NEW HAVEN, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amid the wave of severe respiratory illnesses among children that is pushing hospitals past capacity, multiple federally funded programs - the...
愛科百發在第12屆國際呼吸道合胞病毒（RSV）年會上報告了愛司韋™在RSV感染的住院嬰幼兒中的三期臨床試驗（AIRFLO）積極結果
October 06, 2022 23:39 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中國上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
爱科百发在第12届国际呼吸道合胞病毒（RSV）年会上报告了爱司韦™在RSV感染的住院婴幼儿中的三期临床试验（AIRFLO）积极结果
October 06, 2022 23:39 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium
October 06, 2022 23:39 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Results from Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical)’s successful Phase 3 study (AIRFLO) with the respiratory syncytial...
Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 16:05 ET
|
Icosavax, Inc.
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial...
爱科百发宣布爱司韦™在治疗呼吸道合胞病毒（RSV）感染的住院婴幼儿中的临床三期试验达到主要终点
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在临床三期AirFLO试验中，爱司韦™与安慰剂相比显著降低症状评分（p=0.002）及病毒载量（p=0.006），达到试验主要终点和关键次要终点 RSV感染是五岁以下儿童因病毒感染而住院及死亡的首要因素爱司韦™是全球首个成功在儿童患者人群中完成关键性三期临床研究的RSV抗病毒药物爱司韦™计划于2022年年中向中国监管机构提交新药上市申请 上海, April 07, 2022 (GLOBE...
愛科百發宣佈愛司韋™在治療呼吸道合胞病毒（RSV）感染的住院嬰幼兒中的臨床三期試驗達到主要終點
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
在臨床三期AirFLO試驗中，愛司韋™與安慰劑相比顯著降低症狀評分（p=0.002）及病毒載量（p=0.006），達到試驗主要終點和關鍵次要終點 RSV感染是五歲以下兒童因病毒感染而住院及死亡的首要因素愛司韋™是全球首個成功在兒童患者人群中完成關鍵性三期臨床研究的RSV抗病毒藥物愛司韋™計畫於2022年年中向中國監管機構提交新藥上市申請 上海, April 07, 2022 ...
ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection
April 07, 2022 03:50 ET
|
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3 AirFLO study with ziresovir met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
March 25, 2022 08:00 ET
|
Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...